Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimization of a polypeptide hormone

B Li1, J Y Tom, D Oare

  • 1Department of Protein Engineering, Genenteeh, South San Francisco, CA 94080, USA.

Science (New York, N.Y.)
|December 8, 1995
PubMed
Summary

Researchers successfully shrunk the atrial natriuretic peptide (ANP) hormone by over 40% while maintaining its potency. This involved structural analysis and phage display to create smaller, potent hormone analogs for drug design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A quantitative genetic model for analyzing species differences in outcrossing species.

Biometrics·2000
Same author

Interleukin-12 induces gene expression in interleukin-2 stimulated human T lymphocytes.

European cytokine network·2000
Same author

Depletion of activated alloreactive T cells in prevention of acute graft-versus-host disease.

Transplantation proceedings·2000
Same author

A missense mutation G2320R in the thyroglobulin gene causes non-goitrous congenital primary hypothyroidism in the WIC-rdw rat.

Molecular endocrinology (Baltimore, Md.)·2000
Same author

Proximity relationships between residue 6 of troponin I and residues in troponin C: further evidence for extended conformation of troponin C in the troponin complex.

Biochemistry·2000
Same author

Cloning, expression and characterization of a cDNA (6A8) encoding a novel human alpha-mannosidase.

European journal of biochemistry·2000

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Atrial natriuretic peptide (ANP) is a crucial hormone regulating blood pressure and fluid balance.
  • Reducing the size of peptide hormones can improve their drug-like properties, but often leads to loss of function.
  • Developing smaller, potent peptide hormone analogs is a significant challenge in drug discovery.

Purpose of the Study:

  • To develop a method for significantly reducing the size of atrial natriuretic peptide (ANP) while preserving its biological activity.
  • To identify key structural elements responsible for ANP's receptor binding and activation.
  • To engineer smaller ANP analogs suitable for small-molecule drug design.

Main Methods:

  • Systematic structural and functional analysis of ANP to identify its functional epitope.

Related Experiment Videos

  • Repositioning the native disulfide bond to create a smaller core ring structure.
  • Utilizing phage display technology to optimize non-critical residues and restore binding affinity.
  • Stepwise deletion of flanking residues and subsequent affinity restoration through phage sorting.

    • Main Results:

    • A 15-residue ANP analog was successfully generated from the original 28-residue hormone, retaining high biopotency.
    • A discontinuous functional epitope critical for receptor binding was identified and largely incorporated into the smaller ring structure.
    • Phage display enabled the optimization of remaining residues, restoring high-affinity binding to the receptor.
    • The stepwise reduction and optimization strategy proved effective in creating potent, miniaturized hormone analogs.

    Conclusions:

    • A stepwise approach combining structural analysis and phage display can effectively reduce peptide hormone size while maintaining potency.
    • Hormone miniaturization is feasible by identifying and repositioning critical functional epitopes and optimizing remaining residues.
    • The developed methodology provides a pathway for designing smaller, more drug-like peptide hormone analogs for therapeutic applications.